

# Oncologic Emergencies

---

Stacia Sayner- PA-C

1

## Oncologic Emergencies Overview

- Metabolic
  - SIADH
  - Hypercalcemia of malignancy
- Hematologic
  - Hyper viscosity syndrome
- Structural
  - Spinal cord compression
  - Superior vena cava
- Treatment- related
  - Febrile neutropenia
  - Tumor lysis syndrome

Mercer-Falkoff A, Lacy J. (2013). Oncologic Emergencies. In Oncology in Primary Care, Rose MG, DeVita VT, Lawrence TS, Rosenberg SA (Eds).

2

- Central Nervous System
  - Spinal cord compression
  - Brain metastases
  - Intracranial pressure
  - Seizures
- GI and Urologic
  - Bowel and urinary obstruction
  - Biliary obstruction'
  - cholangitis
  - Malignant ascites
- Cardiothoracic
  - Superior vena cava syndrome
  - Pericardial effusion; tamponade
  - Airway obstruction
  - Massive hemoptysis
  - Malignant pleural effusion
- Metabolic
  - Hypercalcemia of malignancy
  - SIADH
  - Hypoglycemia
  - Lactic acidosis
- Hematologic
  - Thromboembolic events
  - DIC
  - Leukostasis
  - Hyperviscosity Syndrome
- Chemotherapy induced
  - Febrile neutropenia
  - Tumor Lysis Syndrome
  - Diarrhea
  - Cytokine release syndrome
  - Anaphylactic hypersensitivity reactions


3

## Febrile Neutropenia

- FEVER: 1 episode of temperature > 101° F (38.3° C) or temperature 100.4° F (38° C) > 1 hour
- +
- NEUTROPENIA: Absolute neutrophil count (ANC) < 500/mm<sup>3</sup> or an expected ANC < 500/mm<sup>3</sup> within 48 hours<sup>2</sup>
- IDSA Guidelines: Clinical Infectious Diseases 2011; 52(4):e56–e93

4

## Febrile Neutropenia



- Depends on the chemo agent(s) but neutrophil nadir occurs 5-10 days after the last dose of chemo
- Regimens used to treat leukemias and lymphomas tend to cause a longer lasting and more profound neutropenia

Neutropenia	$< 1.0 \times 10^9/L$ (1000/ $\mu L$ )
Severe Neutropenia	$< 0.5 \times 10^9/L$ or ANC that is expected to decrease to this level in 48 hrs (500/ $\mu L$ )
Profound Neutropenia	$< 0.1 \times 10^9/L$ (100/ $\mu L$ )

Netterberg, I., Nielsen, E.I., Fribeg, L.E. et al. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. *Cancer Chemother Pharmacol* 80, 343–353 (2017).

5

## Febrile neutropenia: Pathophysiology

- Few cases of FN will yield a causative organism
- Most common source of infection is patient's own flora
- **Gram positive cocci** (*Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Streptococci viridans*, *Enterococcus faecalis* and *faecium*)
- Gram negative bacilli (*Escherichia coli*, *Klebsiella* species, *Pseudomonas aeruginosa*)
- Fungal: **Candida**, *Aspergillus*, *Zygomycetes*

Zimmer A, Freifeld AG. *J Oncol Pract* 2019;15:19-24

6

## Diagnosis

- Fever may be the sole manifestation of infection
- Detailed history (ROS, antibiotic prophylaxis, history of prior infections, comorbidities)
- Physical exam: skin, catheter sites, oral cavity, lungs, abdomen, GU, perianal; **avoid DRE and medications PR**
- Labs: CBC with diff, CMP, UA, blood x2/urine cultures

7

### Febrile Neutropenia: Risk Stratification



- Anticipated long duration of neutropenia (> 7 days)
- ANC  $\leq 100$  cells/mm<sup>3</sup> or Rapid decline in ANC
- Hemodynamically unstable
- Skin break down; mucositis
- Intravascular catheter infection
- Significant co-morbidity:
  - HTN, PNA, new abdominal pain, neurologic changes
- Hepatic or renal dysfunction



- Anticipated short duration of neutropenia (< 7 days)
- Few co-morbidities; no hepatic or renal dysfunction
- Reliable patient; good support system
- Patients with solid tumors tend to be in the low-risk group

IDSA Guidelines: Clinical Infectious Diseases 2011;52(4):e56–e93

8

## Treatment

- In the absence of adequate neutrophil numbers in circulation, unopposed gram-negative bacteremia has a mortality rate of up to 70% in neutropenic patients who do not receive empiric antibiotics

THUS:

- FN should be treated as a medical emergency

9

## Febrile Neutropenia Tx: Antibiotics

Administer antibiotics within 1 hour of initial presentation: Broad gram-negative and anti-pseudomonal  $\beta$ -lactam agent

- Monotherapy: (normal renal function dosing)
  - Cefepime 2g IV every 8 hours
  - Piperacillin-tazobactam 3.75 vs 4.5g IV every 6-8 hours
- For immediate-type hypersensitivity reaction to penicillin: PJ0
  - Aztreonam + vancomycin
  - Ciprofloxacin + clindamycin

10

Slide 10

---

**PJ0** Some people debate 4.5 g vs 3.75 g  
Preedit, Justine, 2023-08-01T14:08:16.238

## Febrile Neutropenia Tx: G-CSF

- Prophylactic use:
  - After cycle of chemotherapy before neutropenia develops
  - Good evidence to support use in patients with high risk of developing FN
- Therapeutic use :
  - Less evidence supporting use in FN
  - Shortens duration of neutropenia by 2 days on average
  - However, no survival advantage

PJO

J Natl Compr Canc Netw 2020;18(1):12–22. doi: 10.6004/jnccn.2020.0002

11

## Febrile Neutropenia: When to add Vancomycin

- Suspected catheter-related infection
- Suspected soft-tissue infection
- Suspected or proven MRSA
- Known colonization with MRSA
- In case of severe mucositis
- Hemodynamically unstable

PJO

• Zimmer A, Freifeld AG. J Oncol Pract 2019;15:19-24

12

## Slide 11

---

**PJ0** NCCN defines which patients are appropriate for treatment with G-CSF. I would put the name of the agents & dose used somewhere

Preedit, Justine, 2023-08-01T14:08:57.536

## Slide 12

---

**PJ0** Where did you find this info? I don't think this is widely accepted in NCCN/IDSA

Preedit, Justine, 2023-08-01T14:09:26.302

PJO

## Spinal Cord Compression

Definition: Compressive indentation, displacement, or encasement of the thecal sac that surrounds the spinal cord or cauda equina by cancer

### Possible Etiologies:

- Tumor grows into vertebral foramina
- Tumor destroys cortical bone causing a compression fracture
- Tumor metastasizes to the meningeal membranes

Associated with breast, prostate, lung, multiple myeloma

Lawton AJ, et al. Assessment and Management of Patients with Metastatic Spinal

13

## Cord Compression Signs and Symptoms

- Most common presenting symptom is **back pain**
- Back pain may worsen gradually and precedes neurologic symptoms
- Timeline occurs over weeks to months
- Neurologic symptoms: motor weakness, sensory impairment, autonomic dysfunction
- Cauda equina syndrome: urinary retention, overflow incontinence, decreased sensation (buttocks, posterior thighs, perineal regions)

14

**PJ0**    Recommend a pic here  
Preedit, Justine, 2023-08-01T14:14:33.763

## Spinal Cord Compression Workup

- Gold standard for diagnosis is **MRI** and should include entire thecal sac
  - Sensitivity of 93% and specificity of 97%.
- MRI of the entire spine because 20% to 35% of patients have multiple, noncontiguous levels of compression
- When MRI is unavailable or contraindicated, CT scan maybe considered

15

## Treatment of Spinal Cord Compression

- Dexamethasone 10mg or 16mg IV bolus followed by 4mg Q 6 hours (16mg daily in divided doses)
  - DO NOT WAIT FOR MRI prior to giving steroids
- Pain Management
- Consider DVT ppx
- Consults:
  - Radiation Oncology
  - Neurosurgery
  - Medical Oncology

Lawton AJ, et al. Assessment and Management of Patients with Metastatic Spinal

16

External Beam RT	Chemotherapy	Surgery
<ul style="list-style-type: none"> <li>• Lymphoma and multiple myeloma respond well</li> <li>• Prostate and breast CA respond well</li> <li>• Responsiveness of other solid tumors vary</li> </ul>	<ul style="list-style-type: none"> <li>• Lymphoma and multiple myeloma respond well</li> </ul>	<ul style="list-style-type: none"> <li>• Prior spinal irradiation</li> <li>• Unknown primary 10% of spinal cord compression occurs with no known cancer diagnosis</li> <li>• Spinal instability</li> <li>• Compression fracture/bony impingement on cord</li> </ul>

17

## Hypercalcemia of Malignancy

---

Experienced by up to 30% of patients with cancer

---

Among hospitalized patients with hypercalcemia, malignancy is most common cause

---

**Breast, lung, and renal cell carcinomas; multiple myeloma, T-cell leukemia/lymphoma**

---

Prostate cancer, though it often metastasizes to bones, rarely causes hypercalcemia

*JAMA Oncol.* 2023;9(3):430-431. doi:10.1001/jamaoncol.2022.7941

18

## Pathophysiology

- Three mechanisms:
  - Secretion of parathyroid related peptide hormone (PTH-related protein)
    - Seen in squamous cell cancers, renal, bladder, endometrial, lymphoma
    - Poor prognosis; resistant to treatment
  - Bone metastases with local release of osteolytic factors
    - Seen in diseases predisposed to metastasize to bone: breast, prostate; myeloma
    - Responds better to treatment
  - Elevated Serum Calcitriol
    - Hodgkin's lymphoma and some Non-Hodgkin's lymphomas

19

## Signs and Symptoms of Hypercalcemia

- Symptoms tend to be nonspecific; “painful bones, renal stones, abdominal groans, and psychic moans”
- Bone pain usually related to discrete metastases
- Nephrolithiasis can occur
- Abdominal pain from impaired intestinal motility, pancreatitis, constipation, nausea, anorexia
- Changes in mental status from lethargy to coma
- Shortened QT interval → arrhythmias

20

## Grading Hypercalcemia of Malignancy

Classification of Hypercalcemia		
	Corrected Calcium	Ionized Calcium
Mild	< 12 mg/dL	5.6-8 mg/dL
Moderate	12-14 mg/dL	8-10 mg/dL
Severe	> 14 mg/dL	10-12 mg/dL

Calcium	Norm: 9 - 10.5	mg/dL ↗
Albumin	Norm: 3.5 - 5.5	g/dL ↗
Normal albumin: 4 g/dL or 40 g/L	Norm: 3.5 - 5.5	g/dL ↗

Screen grab from MD Calc

21

## Severe Hypercalcemia Management

- Cornerstone of treatment is IV fluids
- For severe hypercalcemia in a patient with no cardiac or renal disease:
  - Vigorous hydration with isotonic saline (i.e., 0.9% NaCl, LR)
  - IV NS at 200-250 mL/hr for 3-4 hours (if tolerated)
  - Maintain urine output 100-150 mL/hour

22

## General Considerations for treatment of HCM



### Management considerations:

Degree of hypercalcemia  
Acuity of Ca<sup>++</sup> increase



Asymptomatic patients with mild or moderate chronic hypercalcemia may not need immediate treatment.



Goal: restore GFR and promote excretion of Na<sup>+</sup> and Ca<sup>++</sup>



Monitor volume and electrolyte status closely

23

## Severe Hypercalcemia Management

- Calcitonin
  - Initial dose 4 IU/kg (intramuscularly or subcutaneously)
  - Repeat serum calcium in 4-6 hours
  - If calcium decreases, can repeat every 12 hours
- Benefits:
  - Acts rapidly (12-24 hours)
  - Can be given before hydration
  - Not nephrotoxic; safe in renal failure
- Disadvantage:
  - Rapid tachyphylaxis (rapid decrease in drug effectiveness)
  - Total duration 24-48 hours
  - High Cost

PJ0

24

**PJ0** Disadvantage: \$\$\$\$

Preedit, Justine, 2023-08-01T14:18:14.940

PJO

## Bisphosphonates

- Osteoclast Inhibitors, Onset of action is 48 hours
- Calcium nadir in 7-10 days
  - Zoledronic acid 4 mg IV over > 15 minutes
  - OR
  - Pamidronate 60-90 mg IV over > 2 hours
- Adverse Events:
  - Nephrotoxicity/nephrotic syndrome
  - Unusual fractures
  - Osteonecrosis of the jaw

25



## TLS pathophysiology

Hyperkalemia » cardiac  
arrhythmias » death

Hyperuricemia » urine  
becomes acidic » uric  
acid crystals deposited  
» renal failure »  
oliguria/anuria

Hyperphosphatemia »  
causes HYPOcalcemia  
» tetany/seizures &  
arrhythmias » renal  
failure

26

## Slide 25

---

**PJ0** To be complete, you should probably mention denosumab (not used in hypercalcemia of malignancy unless refractory to bisphos)  
Preedit, Justine, 2023-08-01T14:19:48.508

## Tumor Lysis Syndrome (TLS)

- Definition: Tumor lysis syndrome (TLS) is an oncologic emergency as a result of tumor cell lysis with the release of intracellular potassium, nucleic acids, and phosphorus into the systemic circulation.
- More common in rapidly proliferating hematologic malignancies, such as ALL, AML, and aggressive lymphomas

PJO

↑	Uric Acid, Potassium, Phosphorus
↓	Calcium

Howard SC. The Tumor Lysis Syndrome. N Engl J Med. 2011; 364:1844-1854.

27

## Cario-Bishop laboratory diagnosis of TLS

Element	Value	Change from baseline
Uric acid	≥476 micromol/L (8 mg/dL)	25% increase
Potassium	≥6.0 mmol/L (or 6 mEq/L)	25% increase
Phosphorus	≥2.1 mmol/L (6.5 mg/dL) for children or ≥1.45 mmol/L (4.5 mg/dL) for adults	25% increase
Calcium	≤1.75 mmol/L (7 mg/dL)	25% decrease

28

## Slide 27

---

**PJ0** I would say "aggressive lymphomas." Did you define ALL/AML yet?

Preedit, Justine, 2023-08-01T14:20:17.462

# Presentation

- Signs and symptoms include:
  - Nausea and/or vomiting
  - Anorexia
  - Fatigue
  - Dark urine or decrease urine output
  - Change in mentation
  - Seizures; hallucinations
  - Muscle cramps
  - Heart arrhythmias and palpitations

29

## Prophylaxis of TLS

- Hydration, hydration, hydration! Hydration is the mainstay for TLS prophylaxis PJ0
  - Ideally 2-3L/m<sup>2</sup> /day IV fluid
- Allopurinol given up to 48 hours before treatment, only prevents new uric acid formation
  - Doses around 300 mg daily, may need dose reduction depending on CrCL
- Rasburicase, a recombinant urate oxidase, converts uric acid into water-soluble allantoin
  - 3mg (1/2 dose) vs 6 mg (full dose) @ Allina Hospital systems
  - Uric acid levels drawn on ice for 72 hours following administration of rasburicase PJ1

Sarno J. Prevention and Management of Tumor Lysis Syndrome in adults with Malignancy. J Adv Pract Oncol. 2013;4(2):101-6

30

## Slide 30

---

**PJ0** Recommend discussing who is candidate for each of these (risk stratifying)

Preedit, Justine, 2023-08-01T14:21:46.682

**PJ1** Heading says "prophylaxis of TLS" - I would never use 6mg of rasburicase for prophylaxis. Also mention \$\$\$

Preedit, Justine, 2023-08-01T14:22:05.151

## Management of TLS

- **Hypocalcemia**

- Asymptomatic
  - No treatment
- Symptomatic – i.e., seizure
  - Calcium gluconate

Treat underlying metabolic abnormalities

- **Hyperphosphatemia**

- Severe
  - Dialysis
- Moderate
  - Restrict phosphate intake
  - Phosphate binders

Howard SC. The Tumor Lysis Syndrome. N Engl J Med. 2011; 364:1844-1854.

31

## TLS treatment

- **Hyperkalemia:**
- Constant cardiac monitoring
- Frequent serum potassium (every 4-6 hours)
- Severe ( $\geq 7.0$  mmol/L) or symptomatic
  - Calcium gluconate (IV) to reduce the risk of cardiac dysrhythmia
  - IV insulin + glucose to drive extracellular potassium into cells
  - Hemodialysis<sup>6</sup>

PJO

32

**PJ0** SPS?

Preedit, Justine, 2023-08-01T14:22:31.886

## TLS Management:

- **Hyperuricemia**
- Continue IV hydration goal to maintain high urine output
- Start allopurinol if not started already
- Rasburicase
  - Breaks down uric acid into more soluble allantoin
  - Not cleared by the kidneys
  - Contraindicated in G6PD deficiency and pregnancy
  - Uric acid level drawn on ice for 72 hours following administration <sup>6</sup>

Adult Rasburicase Dosing	
Indication	Rasburicase dose (mg)
TLS Prophylaxis or Treatment	3 mg
Weight ≥120 kg or uric acid ≥12 mg/dL	6 mg

Howard SC. The Tumor Lysis Syndrome. N Engl J Med. 2011; 364:1844-1854

33

## Oncologic Emergencies Summary

- Oncologic emergencies require prompt identification and intervention
- Prompt management can improve quantity and/or quality of life
- Febrile neutropenia requires prompt blood cultures and initiation of empiric antibiotics
- When spinal cord compression is suspected, steroids should be started immediately
- Hypercalcemia is managed with aggressive hydration and bisphosphonate therapy
- The keys to managing tumor lysis syndrome are prevention, vigilant monitoring of electrolytes, and intervention when needed

34

## References

- Mercer-Falkoff A, Lacy J. (2013). Oncologic Emergencies. In *Oncology in Primary Care*, Rose MG, DeVita VT, Lawrence TS, Rosenberg SA (Eds).
- IDSA Guidelines: *Clinical Infectious Diseases* 2011;52(4):e56–e93
- Netterberg, I., Nielsen, E.I., Fribeg, L.E. et al. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. *Cancer Chemother Pharmacol* 80, 343–353 (2017). <https://link.springer.com/article/10.1007/s00280-017-3366-x>
- *J Natl Compr Canc Netw* 2020;18(1):12–22. doi: 10.6004/jnccn.2020.0002
- Lawton AJ, et al. Assessment and Management of Patients with Metastatic Spinal Cord Compression. *J Clin Oncol.* 2019;37(1): 61-71
- *JAMA Oncol.* 2023;9(3):430-431. doi:10.1001/jamaoncol.2022.7941
- Sarno J. Prevention and Management of Tumor Lysis Syndrome in adults with Malignancy. *J Adv Pract Oncol.* 2013;4(2):101-6.
- Howard SC. The Tumor Lysis Syndrome. *N Engl J Med.* 2011; 364:1844-1854.